NanoSomix to offer Alzheimer’s blood assay for research
A blood test that predicts a patient’s likelihood of developing Alzheimer’s disease has been the target of a multi-center National Institutes of Health study and was recently publicized by the Alzheimer’s Association. Aliso Viego, Calif., based NanoSomiX announced today that it would begin providing the assay to researchers and pharmaceutical companies studying Alzheimer’s treatments this fall.
The central biomarker in the assay is p-tau. The study published in Alzheimer’s & Dementia last month showed that the assay could pick out signs of prodromal Alzheimer’s as early as a decade ahead of symptoms and 96 percent of confirmed Alzheimer’s cases in a study population of 162 patients and healthy controls.
The rights to commercialize are held solely by NanoSomiX. The assays will be disseminated to research institutions working specifically on novel Alzheimer’s treatments.
“Our first blood assay will be available this fall for researchers and pharmaceutical companies that want to use p-tau as a biomarker for drug evaluation or patient sample enrichment in their clinical trials," said John Osth, president and CEO of NanoSomiX, in a statement. "We are interested in collaborating or partnering with pharmaceutical companies to generate additional data."
The blood assay platform will be expanding to encompass not only neurodegenerative disease, but also neuroinflammatory and neurotraumatic disease.